Fuchs-Young R, Howe S, Hale L, Miles R, Walker C
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Mol Carcinog. 1996 Nov;17(3):151-9. doi: 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I.
Uterine leiomyoma is the most frequent gynecologic neoplasm in women. By using a panel of cell lines derived from spontaneous Eker rat leiomyomas, we examined the estrogen-responsive phenotype of these tumor cells. Leiomyoma-derived ELT cell lines proliferated in response to estrogen, and estrogen-induced cell proliferation could be inhibited by the estrogen antagonist ICI 182780 and the selective estrogen-receptor modulators (SERMs) raloxifene and tamoxifen. In addition to inhibiting cell growth, these antagonists also inhibited estrogen-induced increases in progesterone-receptor expression. These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm.
子宫平滑肌瘤是女性中最常见的妇科肿瘤。通过使用一组源自自发性艾克大鼠平滑肌瘤的细胞系，我们检测了这些肿瘤细胞的雌激素反应表型。源自平滑肌瘤的ELT细胞系对雌激素有增殖反应，雌激素诱导的细胞增殖可被雌激素拮抗剂ICI 182780以及选择性雌激素受体调节剂（SERM）雷洛昔芬和他莫昔芬抑制。除了抑制细胞生长外，这些拮抗剂还抑制雌激素诱导的孕激素受体表达增加。这些数据表明，雷洛昔芬和他莫昔芬等SERM在子宫肌层细胞中起雌激素拮抗剂的作用，并提示这类化合物可能对治疗这种重要的妇科肿瘤有效。
